oasis 4 trial semaglutide Oral 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 Investigators present findings from OASIS

Strength points and limitations Based on our knowledge, this is the most updated meta-analysis on this topic, including all available evidence based on our inclusion criteria of including only controlled studies, either RCTs or controlled observational studies, to reach the highest accessible quality of evidence from the available evidence found in the literature

When glutathione levels are low, the body loses its primary defense mechanism, making it harder for the skin to return to a state of balance

In the SURMOUNT-1 Trial (a study on obesity), participants lost up to 24.2% of their body weight over 48 weeks the most significant weight reduction seen in an anti-obesity medication to date

[DOI] [PubMed] [Google Scholar] 173.Takamura T., Misu H., Matsuzawa-Nagata N., et al